Background/aim: To evaluate retrospectively whether bland embolization using microspheres is safe and useful for relieving pain in patients with painful malignant musculoskeletal (MSK) tumors.
Patients And Methods: Bland embolization using microspheres was performed for 20 patients (11 women/9 men) with a median age of 69 years (range=40-89 years) who had 22 painful malignant MSK tumors. The maximum tumor diameters were 2.4-13.8 cm (median, 7.5 cm). Pain was evaluated using the visual analog scale. A decrease of this score by 2 or more after embolization was defined as clinically effective pain relief. Adverse events (AEs) were evaluated using CTCAE v5.0. Objective response, disease control rates, and overall survival were also evaluated.
Results: Effective pain relief was achieved in 18 patients (90.0%, 18/20). Grade-3 AEs developed in four patients (20.0%, 4/20): skin ulcer (n=2), skin ulcer and pain (n=1), and muscle weakness with dysesthesia (n=1). No grade-4 or grade-5 AEs developed. Objective response and disease control rates were 26.7% (4/15) and 86.7% (13/15), respectively. The 1-year survival rate was 43.8%, with median survival of 9.2 months (range=0.5-41.0 months).
Conclusion: Although the survival benefit is equivocal, bland embolization is acceptably safe and useful for relieving pain by controlling tumor growth in patients with painful malignant MSK tumors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347916 | PMC |
| http://dx.doi.org/10.21873/invivo.13272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Locoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
JAMA Netw Open
November 2024
Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Importance: Several locoregional therapies (LRTs) for nonmetastatic hepatocellular carcinoma (HCC) are available; however, a global comparison of the relative efficacy of each is needed.
Objective: To conduct a systematic review and direct, pairwise meta-analytic comparison of all identified randomized clinical trials evaluating the treatment of nonmetastatic HCC.
Data Sources: A comprehensive search of PubMed and the proceedings of the American Society of Clinical Oncology and American Society for Radiation Oncology annual meetings from January 1, 2010, to November 1, 2023, was performed.
Localized hepatocellular carcinoma: Is liver-directed therapy alone as efficacious as surgical resection?
Surgery
November 2024
Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Department of Surgery, Loyola University Medical Center, Maywood, IL. Electronic address:
Objective: Studies of the efficacy of nonsurgical methods of liver-directed therapy (percutaneous microwave or radiofrequency ablation, transarterial bland embolization, chemoembolization, and/or radioembolization) in the treatment of hepatocellular cancer lack contemporaneous comparative surgical cohorts. The role of these methods of liver-directed therapy as destination treatment in hepatocellular cancer is not well defined.
Methods: We queried our institutional registry for patients undergoing resection or liver-directed therapy alone for clinical stage I to IVa hepatocellular cancer between 2012 and 2022.
Efficacy and safety of CalliSpheres drug-eluting bead bronchial arterial infusion chemoembolization vs. bland embolization in advanced lung cancer with hemoptysis: A multicenter retrospective study.
Biomol Biomed
November 2024
Department of Interventional Radiology, Affiliated Hospital of Jining Medical College, Jining, China.
Massive hemoptysis is a life-threatening complication in patients with advanced primary lung cancer, and effective, safe treatments are crucial. This study aimed to investigate the efficacy and safety of CalliSpheres drug-eluting bead bronchial arterial infusion chemoembolization (DEB-BACE) for managing this condition. A retrospective analysis included 144 patients with advanced primary lung cancer and massive hemoptysis treated at multiple hospitals from January 2019 to January 2023.
View Article and Find Full Text PDFMinimally invasive interventional guided imaging therapies of musculoskeletal tumors.
Quant Imaging Med Surg
November 2024
Department of Radiology, MSK Unit, The Clinical Diagnostic Imaging Centre (CDIC), Hospital Clinic, Universitat de Barcelona (UB), Barcelona, Spain.
Article Synopsis
- Historically, musculoskeletal (MSK) tumors have been treated separately, but the complications from metastases, like pain and fractures, require a team of experts to decide on the best treatments, including surgery, radiation, or chemotherapy.
- * Recently, minimally invasive interventional therapies, particularly image-guided ablation techniques, have gained traction as promising options to effectively treat MSK tumors, offering less invasive alternatives.
- * Imaging methods like CT, which is preferred for its accessibility, guide these interventions, which include techniques like radiofrequency ablation and cryoablation, sometimes combined with other treatments for better tumor control.
Locoregional Therapies for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Biomedicines
September 2024
Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43202, USA.
Article Synopsis
- * Many cases of HCC are diagnosed inoperable, necessitating alternative treatment options beyond surgery, despite some cases being treatable through surgical resection or transplantation.
- * This review focuses on key locoregional therapies for HCC in NAFLD patients, such as transarterial chemoembolization (TACE), bland transarterial embolization (TAE), trans
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!